Every 8-K that Curis Inc (CRIS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis, Inc. reports that on July 24, 2026 it received written notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the bid price requirement, and is in full compliance with conditions set by a Nasdaq Hearings Panel.
Under Listing Rule 5815(d)(4)(A), Curis will be subject to a one-year Discretionary Panel Monitor starting July 24, 2026. If Curis fails to meet any continued listing requirement during this period, Nasdaq Staff will issue a Delist Determination Letter and the company must promptly request a new hearing before a Hearings Panel. During the monitor period Curis cannot submit a compliance plan and Staff cannot grant additional time to regain compliance. The company notes there can be no assurance that any appeal would succeed or that its stock will remain listed on Nasdaq, and it includes forward-looking statement cautions referencing risk factors in its Form 10-K for the year ended December 31, 2025.
Curis, Inc. implemented a 1-for-20 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on July 2, 2026. Every 20 issued and outstanding shares of common stock are being converted into one share, with fractional shares rounded up to the nearest whole share.
The reverse split does not change the $0.01 par value or the number of authorized common shares. All outstanding warrants, restricted stock units, stock options and the share reserves under equity incentive plans will be proportionally adjusted. Trading on a split-adjusted basis will begin July 6, 2026, and the stock will continue under the ticker “CRIS” with a new CUSIP 231269408.
Curis, Inc. filed an amended report to update timing details for its previously approved reverse stock split. The Reverse Stock Split Certificate of Amendment is expected to become effective on July 2, 2026 at 5:00 PM ET. Curis common stock is expected to begin trading on The Nasdaq Stock Market on a split-adjusted basis at market open on July 6, 2026. The shares will continue to trade under the ticker symbol “CRIS”, and the common stock will have a new CUSIP number following the reverse split.
Curis, Inc. is implementing a reverse stock split of its common stock at a 1-for-20 ratio. This means every 20 existing shares will be combined into 1 share, reducing the number of shares outstanding while proportionally increasing the price per share.
At a special meeting of stockholders held on June 25, 2026, stockholders approved amendments to the Restated Certificate of Incorporation allowing a reverse split in a range between 1-for-5 and 1-for-25. On the same date, the Board of Directors chose the specific 1-for-20 ratio.
Curis, Inc. held a special stockholder meeting on June 25, 2026, where investors approved a reverse stock split authorization. Stockholders adopted amendments to the Restated Certificate of Incorporation allowing the Board to implement a reverse split of the common stock at a ratio between 1-for-5 and 1-for-25, with discretion to choose the exact ratio or abandon the change.
The reverse split proposal received 26,898,163 votes for, 751,966 against, and 123,820 abstentions. A separate proposal to adjourn the meeting, if needed to secure additional votes, also passed but was not used.
Curis, Inc. reported that stockholders approved a major amendment to its charter to increase total authorized capital stock from 288,757,150 to 572,514,300 shares, including an increase in authorized common stock from 283,757,150 to 567,514,300 shares. The amendment became effective upon filing in Delaware.
The company also filed a Certificate of Elimination to remove the designations for its Series A Convertible Exchangeable Preferred Stock and Series B Convertible Non-Redeemable Preferred Stock, returning those shares to undesignated preferred stock. At the same annual meeting, two Class III directors were re-elected, executive compensation received majority support in a nonbinding vote, and PricewaterhouseCoopers LLP was ratified as independent auditor for the 2026 fiscal year.
Curis, Inc. reported first quarter 2026 results showing a larger net loss as it advances emavusertib across multiple cancer trials. Net loss was $24.2 million, or $1.25 per share, compared with $10.6 million, or $1.25 per share, a year earlier.
The company reported no revenue after selling its Erivedge royalty stream in late 2025, versus $2.4 million in Q1 2025. Research and development expenses fell to $6.4 million, while general and administrative costs rose to $5.1 million, largely from a January 2026 PIPE financing. A new $12.7 million other expense line reflects warrant liability revaluation. Curis ended March 31, 2026 with $15.0 million in cash and cash equivalents and about 40.0 million shares outstanding, and believes existing cash plus potential Series B warrant proceeds could fund operations into the second half of 2027, though it states current cash is insufficient for the next 12 months.
Curis, Inc. reports that Nasdaq has issued a Delist Determination Letter because the bid price of its common stock closed below the $1.00 per share minimum for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). As a result, Curis’ securities are scheduled for suspension and delisting from the Nasdaq Capital Market at the opening of trading on May 6, 2026, unless the company requests a hearing by May 4, 2026. Curis intends to make a timely hearing request, which would stay further delisting actions, but it cautions there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.
Curis, Inc. reported a sharply improved 2025 bottom line, with full-year net loss narrowing to $7.6 million ($0.58 per share) from $43.4 million in 2024, and fourth-quarter 2025 net income of $19.4 million versus a prior-year loss of $9.6 million. Results were driven largely by a non-cash $27.2 million gain from extinguishing the liability tied to the sale of future Erivedge royalties, after Curis sold its Erivedge-related interests and is no longer entitled to royalty revenues. Research and development and general and administrative expenses both declined year over year. As of December 31, 2025, cash and cash equivalents were $5.1 million with about 12.9 million shares outstanding. A January 2026 PIPE financing provides up to $80.8 million in potential gross proceeds, and Curis estimates its cash, including $20.2 million already received and up to $20.2 million from potential Series B warrant exercises, should fund operations into the second half of 2027. The company also notes it does not have sufficient cash on hand to support current operations for 12 months from the press release date and will require substantial additional capital to advance emavusertib.
Curis, Inc. stockholders approved a major increase in the company’s authorized capital and a new long-term equity incentive plan at a special meeting held as a virtual conference.
The amendment to the Restated Certificate of Incorporation raises authorized capital stock from 73,343,750 to 288,757,150 shares and authorized common stock from 68,343,750 to 283,757,150 shares. Stockholders also approved the 2026 Incentive Plan, initially covering 6,407,374 shares plus up to 3,474,867 additional shares from expiring or forfeited prior awards, an annual “evergreen” increase of up to 5% of specified equity outstanding from 2027 through 2036, and up to 25,000,000 shares for incentive stock options. In accordance with Nasdaq Listing Rules 5635(c) and (d), they approved issuing common shares upon conversion of Series B Preferred Stock and exercises of Series A, B and C Warrants (or in some cases pre-funded warrants).
Curis, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(2), meaning its common stock currently meets Nasdaq’s minimum market value of listed securities requirement and the terms set by a Nasdaq Hearings Panel.
Under Nasdaq Listing Rule 5815(d)(4)(A), Curis will remain under a one-year discretionary Panel monitoring period. If it falls out of compliance with any Nasdaq listing rule during this time, it will not receive a cure period or extra time to fix the issue. Instead, Nasdaq staff would issue a delisting determination, after which Curis could request a new hearing, and its securities may ultimately be delisted from Nasdaq.
Curis, Inc. entered into a private PIPE financing, agreeing to sell 20,195 shares of Series B convertible preferred stock bundled with Series A, B and C warrants, each series initially covering 26,926,675 common shares at an exercise price of $0.75 per share. The transaction is expected to provide initial gross proceeds of approximately $20.2 million and could reach about $80.8 million if all warrants are exercised, before fees. Conversion of the preferred and exercisability of the warrants depend on stockholder approval to increase authorized common shares and approve the issuances, and are subject to beneficial ownership caps. Curis estimates that existing cash plus PIPE proceeds, excluding any warrant exercises, will extend its cash runway into 2027 as it focuses development on emavusertib in chronic lymphocytic leukemia and primary central nervous system lymphoma. The company believes the PIPE will help maintain Nasdaq listing compliance through higher stockholders’ equity, but continued listing is not assured.
Curis, Inc. filed an 8‑K/A to add unaudited pro forma financial information related to its completed sale of its interest in Curis Royalty, LLC to TPC Investments Royalty LLC, managed by Oberland Capital.
The filing includes an unaudited pro forma condensed consolidated balance sheet as of September 30, 2025, pro forma statements of operations for the nine months ended September 30, 2025, and for the year ended December 31, 2024, furnished as Exhibit 99.1.
Curis, Inc. (CRIS) completed the sale of its Erivedge business—including its interest in Curis Royalty LLC, Erivedge intellectual property, and its rights under the Genentech license—in exchange for $2.5 million upfront and a release of the company’s liability related to the prior sale of future royalties to Oberland.
The company transferred all related technology and assigned its rights and obligations under the license to Curis Royalty. Curis expects to recognize a gain in Q4 2025 and the liability tied to sold future royalties will be extinguished. Following the sale, Curis will no longer receive revenue under the Erivedge license.
Separately, Nasdaq granted an exception until November 14, 2025 to regain compliance with the market value of listed securities rule. Curis believes, as of this report, that its stockholders’ equity is well above the $2.5 million alternative threshold under Listing Rule 5550(b)(1), though the Panel’s decision is not assured.
Curis, Inc. reported that Nasdaq’s Hearings Panel granted an exception until November 14, 2025 to regain compliance with the Nasdaq Listing Rule 5550(b)(2) market value of listed securities requirement of $35,000,000.
During this period, the company must promptly notify Nasdaq of any significant events affecting compliance, and the Panel may reconsider the exception if circumstances change. The notice states there is no assurance the company will regain compliance or remain listed on Nasdaq.
Curis, Inc. received a delisting notice from Nasdaq after failing to meet the minimum market value of listed securities ($35,000,000) for 30 consecutive trading days. Nasdaq gave a 180‑day compliance period that expired on August 20, 2025, and on August 21, 2025 the Listing Qualifications Staff notified the company that its securities would be delisted unless the company requests a hearing by August 28, 2025. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting while the appeal is pending. The common stock remains listed and tradable on Nasdaq during the appeal, but there is no assurance the company will regain compliance.
Curis, Inc. filed a prospectus supplement under its existing shelf registration to offer and sell up to $8,137,047 of its common stock through an Amended and Restated Sales Agreement with Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC acting as agents. The Shares are registered under the companys Registration Statement and will be offered only by means of the Prospectus Supplement.
The company notified the agents that it terminated a prior prospectus related to an offering of up to $100.0 million, while confirming the Sales Agreement remains in full force and effect. Wilmer Cutler Pickering Hale and Dorr LLP provided a legal opinion and consent included as exhibits. This filing documents terms for a potential equity offering and the related legal opinions; it does not itself constitute a sale of securities.
Curis, Inc. (Nasdaq: CRIS) has entered into a combined $7.0 million capital raise consisting of a registered direct offering and a concurrent private placement. On 2 July 2025, the company executed a Securities Purchase Agreement with institutional investors to sell (i) 1,538,460 registered shares of common stock and (ii) an equivalent number of pre-funded warrants, each paired with five-year common warrants covering in aggregate 3,076,921 shares. The combined purchase price is $2.275 per share/warrant unit for stock and $2.265 for pre-funded warrant units, implying a modest 0.4% discount for the pre-funded tranche. Gross proceeds are expected to total approximately $7.0 million before $0.5 million in placement fees and up to $0.1 million in reimbursable expenses.
Laidlaw & Company (UK) Ltd. and JonesTrading Institutional Services LLC acted as co-placement agents. Shares are being issued off Curis’ effective Form S-3 shelf (File No. 333-276950); the unregistered warrants and underlying shares rely on the Section 4(a)(2)/Rule 506(b) exemption. Closing is targeted on or before 3 July 2025, subject to customary conditions.
The unregistered warrants are immediately exercisable: pre-funded warrants at $0.01 and common warrants at $2.15, each containing beneficial-ownership caps of 4.99% or 9.99% (adjustable up to 19.99% with notice). In certain hostile fundamental transactions, holders may require cash redemption at fair value calculated via a Black-Scholes model.
A Registration Rights Agreement obliges Curis to file a resale shelf for the warrant shares within 60 days of closing and keep it effective for up to five years, with 1% monthly liquidated damages for filing/effectiveness delays (subject to caps).
Management expects net proceeds, together with existing cash, to fund operations into Q1 2026. Curis simultaneously terminated the April 2024 ATM prospectus under its Cantor/Jones at-the-market facility; the Sales Agreement remains in force but new sales require a refreshed prospectus.
Exhibits include the forms of warrants, Purchase Agreement, Registration Rights Agreement, legal opinion, investor deck, and the related press release.